<DOC>
	<DOCNO>NCT00524381</DOCNO>
	<brief_summary>The purpose study evaluate effect tumor necrosis factor alpha ( TNF ) antagonist , etanercept , early clinical course polymyalgia rheumatica ( PMR ) . PMR common inflammatory disease unknown etiology characterize aching , tender , stiff proximal muscle . Some evidence suggest TNF play central role pathophysiology PMR . The preferred treatment glucocorticoid ( GCs ) adequate patient , subset patient prolong , relapse disease course . These patient require treatment GCs 1 2 year . GC related adverse event frequent treatment .</brief_summary>
	<brief_title>Etanercept Treatment Early Course Polymyalgia Rheumatica</brief_title>
	<detailed_description />
	<mesh_term>Polymyalgia Rheumatica</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Persons active polymyalgia rheumatica ( patient ) . Signed informed consent write authorization . Other inflammatory condition polymyalgia rheumatica , include symptom giant cell arteritis , e.g . head ache , jaw claudication visual disturbance . Current malignancy history malignancy . Neuromuscular condition . Infections systemic impact . Uncontrolled diabetes mellitus . Uncontrolled hypertension . Current tuberculosis history tuberculosis . Severe heart failure ( NYHA class 3 4 ) . Current use glucocorticoid , biological drug , immunosuppressive drug . Exclusion Criteria ( control ) : Polymyalgia rheumatica .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>